Stock futures rise slightly as investors brace for a big Fed rate hike

Stock futures rise slightly as investors brace for a big Fed rate hike


Stock futures rose slightly in overnight trading Tuesday as investors anxiously awaited the Federal Reserve’s aggressive action to tame surging inflation.

Futures on the Dow Jones Industrial Average gained 70 points. S&P 500 futures edged up 0.3% and Nasdaq 100 futures rose 0.4%.

The S&P 500 suffered a five-day losing streak on Tuesday, dipping deeper into bear market territory. The equity benchmark has fallen more than 4% this week already and is now off over 22% from its all-time time hit in early January. The blue-chip Dow slid about 150 points Tuesday, also falling for a fifth straight day Tuesday. The Nasdaq Composite ended Tuesday slightly higher.

The rate-setting Federal Open Market Committee will conclude its two-day meeting on Wednesday. The market is betting on a 94% chance of a 75-basis-point rate hike, the biggest increase since 1994, according to the CME Group’s FedWatch tool. (1 basis point equals 0.01%)

The shift to price in a larger-than-usual rate hike came after headlines that Fed officials were contemplating such a move following a surprisingly hot inflation reading as well as worsening economic outlook.

“The change in the headline from 50 basis points to 75 basis points reflects a stark reality but it also reflects the Fed’s determination to underscore its commitment to its mandate to maintain price stability,” said Quincy Krosby, chief equity strategist at LPL Financial. “It’s neither a trial balloon nor a lead balloon — it’s reality.”

Fed Chair Jerome Powell will hold a press conference at 2:30 p.m. ET following the central bank’s policy decision. Investors will be monitoring his language and tone about the Fed’s tightening path forward. The central bank will also release its outlook for its benchmark rate, inflation and GDP.

Treasury yields have jumped dramatically this week in anticipation of the big rate hike. The two-year rate, most sensitive to changes in monetary policy, surged 40 basis points this week alone to hit its highest level since 2007. The benchmark 10-year yield popped more than 30 basis points to top 3.48%, a high not seen since April 2011.

Some notable investors believe the central bank can regain credibility by acting aggressively to show its seriousness in combating inflation.

The Fed “has allowed inflation to get out of control. Equity and credit markets have therefore lost confidence in the Fed,” wrote Pershing Square’s Bill Ackman in a tweet Tuesday. “Market confidence can be restored if the Fed takes aggressive action with 75 bps tomorrow and in July” and makes a commitment to aggressive increases until inflation “has been tamed.”



Source

Fed Governor Miran submits resignation, throws support behind Warsh as new chair
Finance

Fed Governor Miran submits resignation, throws support behind Warsh as new chair

Key Points Fed Governor Stephen Miran officially handed in his resignation letter Thursday, saying he will vacate his spot on the central bank board when or just before new Chair Kevin Warsh takes his seat. Miran has advocated for lower rates, voting against the three quarter-percentage-point reductions the FOMC approved in 2025. This year, he […]

Read More
Some short sellers are seeing opportunity in this tech mania. How they’re spotting fake AI stocks
Finance

Some short sellers are seeing opportunity in this tech mania. How they’re spotting fake AI stocks

Key Points Some short sellers argue the AI-driven rally is beginning to resemble previous speculative manias. Weaker companies rushed to attach themselves to the hottest market theme in hopes of attracting capital and retail traders. Source

Read More
Stocks making the biggest moves premarket: Versant, Biogen, Bullish, Cisco and more
Finance

Stocks making the biggest moves premarket: Versant, Biogen, Bullish, Cisco and more

Check out the companies making the biggest moves in premarket trading: Biogen — Shares advanced 4% after the biopharmaceutical company announced its experimental Alzheimer’s drug will advance into a phase 3 trial, despite failing to meet the main goal of the phase 2 trial. Biogen said the drug showed cognitive benefits. Versant Media Group – […]

Read More